MFS International Equity Fund
MFS Series Trust XVII · Series S000002537 · 3 share classes
data updated 2026-08-10
Fund profile
As filed in the prospectus · 2025 Q4
The funds investment objective is to seek capital appreciation.
The fund invests at least 80% of assets in foreign equity securities selected through bottom-up fundamental analysis, with no constraint on investment style, company size, or sector concentration. MFS may hold a significant percentage in a single industry, sector, country, or region. Because the fund's performance depends on the success of individual security selections rather than tracking an index, divergence from any peer benchmark will reflect the manager's stock-picking decisions.
| Share class | Gross | Net |
|---|---|---|
| MIEIX | 0.65% | 0.64% |
| MIEJX | 0.99% | 0.98% |
| MIEKX | 0.74% | 0.73% |
Net is what a holder pays after the adviser's contractual waiver; gross is before it. A waiver can expire.
Portfolio turnover 13.00% · as of 2025 Q4
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q1
| Stocks | 98.05% |
| Cash & short-term | 2.04% |
Latest quarter
What changed since the fund's previous filing
New: Roche Holding AG, GSK plc, QIAGEN NV, Danish Krone
Exited: Roche Holding AG, QIAGEN NV, Dassault Systemes SE, Tata Consultancy Services Ltd., Linde plc, EssilorLuxottica SA
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Feb 2026
| Share class | 1-year | 3-year | 5-year | Vol | Worst fall |
|---|---|---|---|---|---|
| — | — | — | — | — | |
| — | — | — | — | — | |
| — | — | — | — | — |
Mar 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Value | Shares |
|---|---|---|---|---|
| — | Taiwan Semiconductor Manufacturing Co. Ltd. | 3.42% | $981.55M | 17.4M |
| — | Air Liquide SA | 2.81% | $806.74M | 3.9M |
| — | Novartis AG | 2.79% | $800.83M | 5.3M |
| — | Roche Holding AG | 2.71% | $778.69M | 2.0M |
| — | TotalEnergies SE | 2.45% | $703.60M | 7.6M |
| — | Hitachi Ltd. | 2.39% | $687.07M | 23.5M |
| — | Schneider Electric SE | 2.33% | $670.17M | 2.4M |
| — | Rolls-Royce Holdings plc | 2.05% | $589.47M | 38.6M |
| — | Deutsche Boerse AG | 2.03% | $583.83M | 2.0M |
| — | Mitsubishi Electric Corp. | 2.02% | $579.67M | 17.8M |
Top 10 positions are 25.02% of net assets, top 25 52.16%, across 82 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free